12. Lussier C, Basora N, Bouatrouss Y, Beaulieu JF (2000) Integrins as mediators of epithelial cell-matrix interactions in the human small intestinal mucosa. Microsc Res Tech 51: 169–178. 13. Dignass AU (2001) Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 7: 68–77. 14. Czerucka D, Piche T, Rampal P (2007) Review article: yeast as probiotics – Saccharomyces boulardii. Aliment Pharmacol Ther 26: 767–778. 15. Canonici A, Siret C, Pellegrino E, Pontier-Bres R, Pouyet L, et al. (2011) Saccharomyces boulardii improves intestinal cell restitution through activation of the alpha2beta1 integrin collagen receptor. PLoS ONE 6: e18427. 16. Pothoulakis C (2009) Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 30: 826–833. 17. Buts JP, De Keyser N (2010) Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa. Scand J Gastroenterol 45: 175–185. 18. McFarland LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202–2222. 19. Plein K, Hotz J (1993) Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea–a pilot study. Z Gastroenterol 31: 129–134. 20. Guslandi M, Giollo P, Testoni PA (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 697–698. 21. Girard P, Pansart Y, Coppe MC, Gillardin JM (2005) Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon. Dig Dis Sci 50: 2183–2190. 22. Dalmasso G, Loubat A, Dahan S, Calle G, Rampal P, et al. (2006) Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC- infected T84 cells. Res Microbiol 157: 456–465. 23. Mammen JM, Matthews JB (2003) Mucosal repair in the gastrointestinal tract. Crit Care Med 31: S532–537. 24. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, et al. (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83: 497–505. 25. Vermeulen SJ, Bruyneel EA, Bracke ME, De Bruyne GK, Vennekens KM, et al. (1995) Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res 55: 4722–4728. 26. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449–24454. 27. Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, et al. (2008) Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer 122: 572–582. 28. Gorvel JP, Ferrero A, Chambraud L, Rigal A, Bonicel J, et al. (1991) Expression of sucrase-isomaltase and dipeptidylpeptidase IV in human small intestine and colon. Gastroenterology 101: 618–625. 29. Defilles C, Montero MP, Lissitzky JC, Rome S, Siret C, et al. (2011) alphav integrin processing interferes with the cross-talk between alphavbeta5/beta6 and alpha2beta1 integrins. Biol Cell 103: 519–529. 30. Defilles C, Lissitzky JC, Montero MP, Andre F, Prevot C, et al. (2009) alphavbeta5/beta6 integrin suppression leads to a stimulation of alpha2beta1 dependent cell migration resistant to PI3K/Akt inhibition. Exp Cell Res 315: 1840–1849. 31. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC (2011) Anti- inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 301: G1083–1092. 32. Singh B, Su YC, Riesbeck K (2010) Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 78: 545–560. Sb Modulates avb5 Integrin Activity 33. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ (2003) Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349: 350–357. 34. Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, et al. (1996) Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110: 1077–1083. 35. Ido A, Numata M, Kodama M, Tsubouchi H (2005) Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 40: 925–931. 36. Chantret I, Rodolosse A, Barbat A, Dussaulx E, Brot-Laroche E, et al. (1994) Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation. J Cell Sci 107 (Pt 1): 213–225. 37. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z (2003) Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144: 2807–2815. 38. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604–617. 39. Hallstrom T, Blom AM, Zipfel PF, Riesbeck K (2009) Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J Immunol 183: 2593–2601. 40. Chavakis T, Kanse SM, Lupu F, Hammes HP, Muller-Esterl W, et al. (2000) Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96: 514–522. 41. Preissner KT, Reuning U (2011) Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37: 408–424. 42. Banno A, Ginsberg MH (2008) Integrin activation. Biochem Soc Trans 36: 229– 234. 43. Zaidel-Bar R, Itzkovitz S, Ma’ayan A, Iyengar R, Geiger B (2007) Functional atlas of the integrin adhesome. Nat Cell Biol 9: 858–867. 44. Owen KA, Abshire MY, Tilghman RW, Casanova JE, Bouton AH (2010) FAK regulates intestinal epithelial cell survival and proliferation during mucosal wound healing. PLoS ONE 6: e23123. 45. Andre´ F, Rigot V, Thimonier J, Montixi C, Parat F, et al. (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83: 497–505. 46. Adair JE, Stober V, Sobhany M, Zhuo L, Roberts JD, et al. (2009) Inter-alpha- trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem 284: 16922–16930. 47. Upton Z, Wallace HJ, Shooter GK, van Lonkhuyzen DR, Yeoh-Ellerton S, et al. (2011) Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds. Int Wound J 8: 522–532. 48. Huttenlocher A, Horwitz AR (2011) Integrins in cell migration. Cold Spring Harb Perspect Biol 3: a005074. 49. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF (1997) Integrin-ligand binding properties govern cell migration speed through cell- substratum adhesiveness. Nature 385: 537–540. 50. Buts JP (2009) Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 54: 15–18. 51. Zanello G, Meurens F, Berri M, Salmon H (2009) Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol 11: 47–58. 52. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, et al. (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69–76. 53. Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, et al. (2005) [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor- gamma in HT-29 cells]. Korean J Gastroenterol 45: 328–334. PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e45047